CSPC Innovation Pharmaceutical Co Ltd Class A Cash Flow Conversion Efficiency
CSPC Innovation Pharmaceutical Co Ltd Class A cash flow conversion efficiency. Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) has a cash flow conversion efficiency ratio of -0.009x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-25.98 Million ≈ $-3.80 Million USD) by net assets (CN¥2.80 Billion ≈ $409.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
Cash flow conversion efficiency of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025. This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of CSPC Innovation Pharmaceutical Co Ltd Cl for real-time trading data and today's change.
CSPC Innovation Pharmaceutical Co Ltd Class A Cash Flow Conversion Ratio Explained
CSPC Innovation Pharmaceutical Co Ltd Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CSPC Innovation Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency. Also see CSPC Innovation Pharmaceutical Co Ltd Cl stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MERUS N.V. EO -09
F:2GH
|
N/A |
|
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság
F:MGYB
|
0.097x |
|
Madison Square Garden Sports Corp
NYSE:MSGS
|
-0.200x |
|
OR Royalties Inc.
TO:OR
|
0.056x |
|
Indian Overseas Bank
NSE:IOB
|
-0.682x |
|
PrairieSky Royalty Ltd
TO:PSK
|
0.048x |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
-0.148x |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
0.130x |
Annual Cash Flow Conversion Efficiency for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual cash flow conversion efficiency of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025. Review free cash flow generation of CSPC Innovation Pharmaceutical Co Ltd Cl to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.80 Billion ≈ $409.04 Million |
CN¥-195.69 Million ≈ $-28.64 Million |
-0.070x | +74.52% |
| 2024-12-31 | CN¥4.50 Billion ≈ $657.90 Million |
CN¥-1.24 Billion ≈ $-180.73 Million |
-0.275x | -262.45% |
| 2023-12-31 | CN¥5.48 Billion ≈ $802.37 Million |
CN¥927.24 Million ≈ $135.68 Million |
0.169x | +4.10% |
| 2022-12-31 | CN¥3.94 Billion ≈ $577.16 Million |
CN¥640.72 Million ≈ $93.76 Million |
0.162x | +83.40% |
| 2021-12-31 | CN¥3.30 Billion ≈ $482.55 Million |
CN¥292.09 Million ≈ $42.74 Million |
0.089x | -31.82% |
| 2020-12-31 | CN¥2.69 Billion ≈ $393.18 Million |
CN¥349.07 Million ≈ $51.08 Million |
0.130x | -0.51% |
| 2019-12-31 | CN¥2.42 Billion ≈ $353.44 Million |
CN¥315.38 Million ≈ $46.15 Million |
0.131x | -18.30% |
| 2018-12-31 | CN¥999.35 Million ≈ $146.24 Million |
CN¥159.73 Million ≈ $23.37 Million |
0.160x | +9327.66% |
| 2017-12-31 | CN¥766.93 Million ≈ $112.23 Million |
CN¥1.30 Million ≈ $190.26K |
0.002x | -99.29% |
| 2016-12-31 | CN¥572.02 Million ≈ $83.70 Million |
CN¥137.27 Million ≈ $20.09 Million |
0.240x | +34.25% |
| 2015-12-31 | CN¥626.83 Million ≈ $91.72 Million |
CN¥112.05 Million ≈ $16.40 Million |
0.179x | +2.85% |
| 2014-12-31 | CN¥537.16 Million ≈ $78.60 Million |
CN¥93.36 Million ≈ $13.66 Million |
0.174x | -- |
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food product… Read more